News

BioVie Unveils Phase 2 Study Plan for Bezisterim Against Long COVID

BioVie Unveils Phase 2 Study Plan for Bezisterim Against Long COVID

BioVie Announces Phase 2 Study Design for Bezisterim in Long COVID

BioVie Inc. (NASDAQ: BIVI) has made headlines with its recent announcement regarding the design of a planned Phase 2 clinical trial for bezisterim, aimed at treating Long COVID. The company, which specializes in developing advanced therapies for neurological and neurodegenerative diseases, presented this significant development ahead of its presentation at a prominent international conference on Long COVID.

Details of the Planned Phase 2 Study

The upcoming Phase 2 study focuses on evaluating the effectiveness and safety of bezisterim for Long COVID symptoms. This double-blind, randomized, placebo-controlled trial will involve approximately 200 participants, a substantial number aimed at gathering conclusive results. Funded entirely by a grant from the U.S. Department of Defense, the study seeks to assess how a three-month treatment course with bezisterim might alleviate neurocognitive symptoms associated with Long COVID.

Conference Presentation Details

BioVie has confirmed that the abstract detailing their study has been accepted for presentation in poster format. The specifics are:

Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
Poster Number: 28
Presentation Date: November 21, 2024
Presenter: Penelope Markham, Ph.D., Senior Vice President and Program Lead, Long COVID, BioVie Inc.

Understanding Long COVID

Long COVID is a complex condition that arises after the initial COVID-19 infection. Symptoms can persist long after recovery from the acute phase, affecting nearly 6.8% of adults in the U.S., translating to over 17 million people. This condition is marked by a variety of symptoms such as persistent fatigue, cognitive challenges often referred to as 'brain fog', and loss of smell and taste, among others. Recent evaluate reports indicate that the prevalence might be as high as 22%, emphasizing the need for effective treatments.

The Economic Impact of Long COVID

The repercussions of Long COVID are profound, not just on individual health but also on the economy. The staggering estimated cost of $3.7 trillion highlights the potential role of healthcare providers and pharmaceutical advancements in addressing these long-term challenges. No effective pharmacological or non-pharmacological treatments are currently available, accentuating the urgency for research and development in this arena.

Backing from the U.S. Department of Defense

This Phase 2 study is backed by a substantial award of $13,137,150 via the Peer Reviewed Medical Research Program (PRMRP) granted by the U.S. Department of Defense. Their support showcases the importance of addressing health issues emerging from the COVID pandemic, and highlights BioVie’s commitment to advancing treatment options for such complex conditions.

About BioVie Inc.

BioVie Inc. has been at the forefront of developing cutting-edge therapies for neurological conditions, including Long COVID, Alzheimer’s disease, and Parkinson’s disease. Their innovative approach with bezisterim aims to tackle not just the symptoms but also the underlying neuroinflammation and insulin resistance that contribute to these conditions. Furthermore, BioVie is actively pursuing the clinical evaluation of BIV201, an orphan drug for liver disease treatment, which has garnered FDA Fast Track status.

Frequently Asked Questions

What is the aim of the Phase 2 study for bezisterim?

The Phase 2 study aims to evaluate the safety, tolerability, and potential efficacy of bezisterim in treating neurocognitive symptoms linked to Long COVID.

Who is funding the study?

The study is fully funded by a grant from the U.S. Department of Defense, amounting to $13,137,150.

What are the common symptoms of Long COVID?

Long COVID symptoms can include extreme fatigue, cognitive challenges, loss of taste and smell, and persistent respiratory and cardiovascular issues.

How prevalent is Long COVID among adults in the U.S.?

Recent studies show that approximately 6.8% of adults in the U.S. are currently living with Long COVID, which may potentially be as high as 22% based on real-world data.

What is the significance of BioVie’s research efforts?

BioVie’s research represents a critical step towards developing effective treatments for Long COVID, a condition currently lacking proven pharmacological interventions, highlighting the company's role in addressing post-COVID complications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 211

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 104

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 68

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 56

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 142

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Art of Taiko Drumming at Asano Taiko Factory Tour

Updated Category News Views 142

Step into the World of Taiko Drumming at Asano Have you ever experienced the powerful beats of a taiko drum? Located in Japan, Asano Taiko offers an immersive journey into the fascinating world of taiko drumming. With over 400 years of tradition behind them, Asano Taiko is renowned for its craftsmanship, making it one of the leading manufacturers of traditional Japanese...

Continue Reading
Critical Foot Care Initiative by Forté Orthopedic and Colts

Updated Category News Views 193

Critical Support for Foot Health Needs In the heart of Indiana, a remarkable initiative is transforming the lives of those in need. Forté Orthopedic Research Institute has joined forces with the Indianapolis Colts to create an event called Hearts 2 Soles. This annual event is dedicated to improving foot health among the unhoused community. People facing homelessness...

Continue Reading
Options Activity Sparks Interest in First Majestic Silver

Updated Category News Views 212

Investors Show Strong Interest in First Majestic Silver Recent developments in the options market indicate that investors are making significant bets on First Majestic Silver (NYSE: AG). This heightened activity could be a sign of underlying trends that investors should monitor closely. What We See in the Options Market The surge in options trading for AG has caught the...

Continue Reading
Projected Surge in Enterprise GenAI Spending for 2025

Updated Category News Views 174

The Future of Enterprise Investment in GenAI Enterprises are looking forward to a significant return on investment (ROI) from generative AI (GenAI) projects by 2025. Expectations predict a 50% increase in spending, as companies shift their priorities from simply boosting efficiency to enriching human expertise with advanced technologies. Key Findings from Recent Research...

Continue Reading
Liquidity Services Expands with Auction Software Purchase

Updated Category News Views 226

Liquidity Services Enhances Its Software Offerings Liquidity Services, Inc. (NASDAQ:LQDT), a prominent player in the global commerce sector, has recently made headlines with its acquisition of Auction Software, a recognized leader in auction and marketplace technology. This step is outlined as a strategic move to boost Liquidity Services’ capabilities in the Circular...

Continue Reading